Compare Kodiak Gas Services Inc. Common Stock (KGS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kodiak Gas Services Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Kodiak Gas Services Inc. Common Stock trades at $50.07 (market cap $5.26B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Kodiak Gas Services Inc. Common Stock pays a 3.77% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kodiak Gas Services Inc. Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KGS | SYRE | |
|---|---|---|
Market Cap | $5.26B | $7.52B |
Volume | 2,807,958 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $76.27 | $108.92 |
52-Week Low | $32.95 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $7.94B | $6.52B |
Dividend Yield | 3.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KGS trades at $52.00, down 0.93% on the day, with technical indicators showing a bearish trend. The company reported Q2 2026 revenue growth but missed earnings expectations for three consecutive quarters. Recent developments include a significant power supply agreement for West Texas data centers, positioning KGS for future growth in distributed power generation.
Despite recent earnings misses, analyst consensus remains strongly bullish with a $80.38 price target representing 55% upside potential. Key risks include execution challenges in expanding power capacity and continued earnings volatility. The company's strategic pivot toward data center power services offers substantial growth opportunity if successfully executed.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kodiak Gas Services Inc. Common Stock
Kodiak Gas Services, Inc. is a Texas-based provider of large-horsepower contract natural gas compression services, operating a fleet of roughly 4.5 million revenue-generating horsepower for oil and gas producers and midstream companies across major US production basins, including the Permian, Eagle Ford, and DJ Basin.
Read more on KGS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
